SCHEMBL7836096

SCHEMBL7836096

[CH2]c1ccc2cccc(OCC(C)C)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
CYP2C19 P33261 1/20 0.46
KMT2A Q03164 1/20 0.46
NR2E1 Q9Y466 7/20 0.46
CYP2D6 P10635 4/20 0.43
ADRB2 P07550 4/20 0.43
ADRB1 P08588 4/20 0.43
SIGMAR1 Q99720 4/20 0.43
HTR1B P28222 4/20 0.43
SLC6A4 P31645 3/20 0.43
HTR2B P41595 3/20 0.43
ALDH1A1 P00352 3/20 0.43
ADRB3 P13945 3/20 0.43
HTR2A P28223 3/20 0.43
HTR2C P28335 3/20 0.43
HTR6 P50406 3/20 0.43
TSHR P16473 3/20 0.43
SCN1A P35498 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7836099 0.82 CYP1A2 (0.50) CYP1A2KDM4EMEN1CYP2C19KMT2A
SCHEMBL29829725 0.81 NR2E1 (0.64) CYP1A2KDM4EMEN1CYP2C19KMT2A
SCHEMBL5031818 0.81 NR2E1 (0.64) CYP1A2KDM4EMEN1CYP2C19KMT2A
SCHEMBL7835592 0.81 HTR1B (0.48) HTR1BSLC6A4
SCHEMBL3767592 0.78 TLR8 (0.50) CYP1A2KDM4EMEN1CYP2C19KMT2A
SCHEMBL7822958 0.73 GABRA1 (0.44) CYP1A2CYP2C19CYP2D6ADRB2SIGMAR1
SCHEMBL7834560 0.73 CYP2D6 (0.46) CYP1A2KDM4EMEN1CYP2C19KMT2A
SCHEMBL11605265 0.73 ALDH1A1 (0.47) CYP1A2KDM4EALDH1A1TLR8
SCHEMBL31094211 0.72 NR2E1 (0.43) CYP1A2KDM4EMEN1CYP2C19KMT2A
SCHEMBL19683357 0.72 NR2E1 (0.44) CYP1A2KDM4EMEN1CYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0676398-B1 Heterocyclic compounds having anti-diabetic activity, their preparation and their use SANKYO CO (JP) 2001-10-24 EP disclosed
CN-1066729-C Benzimidazole derivatives, their preparation and their therapeutic use SANKYO CO (JP) 2001-06-06 CN disclosed
US-6117893-A Heterocyclic compounds having anti-diabetic activity and their use SANKYO COMPANY, LIMITED (JP) 2000-09-12 US disclosed
EP-1022274-A1 Oxazolidinedione and Thiazolidinedione derivatves, their preparation and their use Sankyo Company Limited (JP) 2000-07-26 EP disclosed
US-5977365-A HYPOGLYCEMIC AGENTS SANKYO COMPANY, LIMITED (JP) 1999-11-02 US disclosed
US-5962470-A Heterocyclic compounds having anti-diabetic activity and their use SANKYO COMPANY, LIMITED (JP) 1999-10-05 US disclosed
US-5886014-A TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS SANKYO COMPANY, LIMITED (JP) 1999-03-23 US disclosed
US-5834501-A TREATING DIABETES OR HYPERLIPEMIA SANKYO COMPANY, LIMITED (JP) 1998-11-10 US disclosed
US-5739345-A HYPOGLYCEMIC AND ANTIDIABETIC AGENTS SANKYO COMPANY, LIMITED (JP) 1998-04-14 US disclosed
CN-1157288-A Benzimidazole derivatives, their preparation and their therapeutic use SANKYO CO (JP) 1997-08-20 CN disclosed
US-5624935-A ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS SANKYO COMPANY, LIMITED 1997-04-29 US disclosed
EP-0745600-A1 Benzimidazole derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1996-12-04 EP disclosed
EP-0676398-A2 Heterocyclic compounds having anti-diabetic activity, their preparation and their use SANKYO COMPANY LIMITED (JP) 1995-10-11 EP disclosed